HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.

AbstractBACKGROUND:
Dll4/Notch and Ephrin-B2/EphB4 pathways play critical roles in tumor vessel development and maturation. This study evaluates the efficacy of the inhibition of both signaling pathways, alone and in combination, in reducing the growth of an autochthonous mouse tumor and assesses potential adverse effects.
METHODS:
We used the transgenic RIP1-Tag2 tumor model to study the effects of 1) inhibition of Dll4/Notch by either Dll4 allelic deletion or use of a soluble extracellular Dll4 (sDll4), 2) inhibition of Ephrin-B2/EphB4 signaling by a soluble extracellular EphB4 fused to albumin (sEphB4-Alb), and 3) inhibition of both pathways by sEphB4-Alb combined with either Dll4 allelic deletion or sDll4. To investigate adverse effects, we used inducible endothelial-specific Dll4 knock-out mice, treated with sEphB4-Alb, and carried out histopathological analysis.
RESULTS:
Dll4 allele deletion or soluble Dll4 treatment resulted in increased tumor vessel density, reduced mural cell recruitment and vessel perfusion which resulted in reduced tumor size. The soluble EphB4 instead reduced vessel density and vessel perfusion, leading to reduction of tumor size. Greater efficacy was observed when sEphB4-Alb was combined with either Dll4 allele deletion or sDll4 in regards to tumor size, vessel perfusion and mural cell recruitment. Induced endothelial specific Dll4 loss-of-function caused hepatic vascular alterations, which were prevented by concomitant sEphB4-Alb treatment.
CONCLUSION:
Combination targeting of Dll4/Notch and Ephrin-B2/EphB4 has potential for clinical investigation, providing cumulative efficacy and increased safety over Dll4/Notch inhibition alone.
AuthorsDusan Djokovic, Alexandre Trindade, Joana Gigante, Marina Badenes, Lilliana Silva, Ren Liu, Xiuqing Li, Ming Gong, Valery Krasnoperov, Parkash S Gill, Antonio Duarte
JournalBMC cancer (BMC Cancer) Vol. 10 Pg. 641 (Nov 23 2010) ISSN: 1471-2407 [Electronic] England
PMID21092311 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Adaptor Proteins, Signal Transducing
  • Angiogenesis Inhibitors
  • Calcium-Binding Proteins
  • DLL4 protein, mouse
  • Ephrin-B2
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • Receptors, Notch
  • Recombinant Fusion Proteins
  • Ephb4 protein, mouse
  • Receptor, EphB4
Topics
  • Adaptor Proteins, Signal Transducing
  • Angiogenesis Inhibitors (administration & dosage)
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Calcium-Binding Proteins
  • Endothelial Cells (drug effects, metabolism)
  • Ephrin-B2 (metabolism)
  • Genetic Therapy
  • Insulinoma (blood supply, genetics, metabolism, therapy)
  • Intracellular Signaling Peptides and Proteins (deficiency, genetics, metabolism)
  • Membrane Proteins (deficiency, genetics, metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Molecular Targeted Therapy
  • Neovascularization, Pathologic (genetics, metabolism, prevention & control)
  • Pancreatic Neoplasms (blood supply, genetics, metabolism, therapy)
  • Receptor, EphB4 (metabolism)
  • Receptors, Notch (metabolism)
  • Recombinant Fusion Proteins (administration & dosage)
  • Signal Transduction (drug effects)
  • Time Factors
  • Tumor Burden

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: